[A20-58] Ribociclib (breast cancer, combination with fulvestrant) - Addendum to commission A20-22

Last updated 20.08.2020

Project no.:

Commission awarded on 06.07.2020 by the Federal Joint Committee (G-BA).

Report type:

Commission completed

Drug Assessment

Application field:


Initial endocrine therapy or after prior endocrine therapy in postmenopausal women with HR-positive, HER2-negative locally advanced or metastatic breast cancer

Result of dossier assessment:

Conclusion of dossier assessment A20-22 unchanged: for patients with initial endocrine therapy, indication of minor added benefit; for patients who have already received prior endocrine therapy, added benefit not proven.


If the need for additional work on a project commissioned by the G-BA arises during consultations, then IQWiG presents a report in the form of an "addendum". The G-BA subsequently decides on the extent of the added benefit, thus completing the early benefit assessment.

Accompanying information

Further information for consumers and patients is provided on IQWiG's health information website www.informedhealth.org.

Federal Joint Committee (G-BA)

2020-08-20: A G-BA decision was published.

G-BA documents on this decision


Info Service

Subscribe to daily updated information on projects, calls for tender, and events as well as our press releases.

Contact form

Questions about commissions, publications and press releases can be sent to us via this form.